Focus: Novartis is a globally diversified pharmaceutical giant with 78,000 employees headquartered in Basel, Switzerland, operating across oncology, immunology, neuroscience, cardiovascular, and ophthalmology. The company is a major player in small molecules, vaccines, and biologics with significant revenue concentration in peak-stage products.
Profile data last refreshed 40m ago · AI intelligence enriched 2w ago
Hot — 632 jobs added in 30d
Net +183 (632 new, 449 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 408 affected
Source: state DOL filings via Big Local News
A stable Big Pharma with strong diversification and pipeline depth, but near-term patent cliff pressures and revenue concentration warrant caution on long-term role security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship cardiovascular product generating 54% of company revenue; patent protection extends to 2036 but faces significant generic erosion risk post-LOE.
Help build intelligence for Novartis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novartis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-tier immunology product losing exclusivity in 14 months; represents the most immediate commercial and organizational threat to career stability.
Oncology franchise pillar with extended protection; demonstrates Novartis's strength in kinase inhibitor space.
CDK4/6 inhibitor with strong growth trajectory and extended patent protection; core oncology franchise driver.
449 discontinued, 225 duplicate formulations not shown
+50 more products with revenue data
8-K Filing: Rigetti Computing, Inc. (RGTI, RGTIW) (CIK 0001838359) — EXHIBIT 10.1
EXHIBIT 10.1
8-K Filing: Neurogene Inc. (NGNE) (CIK 0001404644) — EX-99.1
EX-99.1
8-K Filing: Aktis Oncology, Inc. (AKTS) (CIK 0002035832) — EX-99.1
EX-99.1
8-K Filing: Ionetix Corp / DE / (CIK 0002108121) — CURRENT REPORT
CURRENT REPORT
8-K Filing: Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425) — EX-99.1
EX-99.1
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
+203 more products
Recent restructuring and spin-off activities create near-term role instability; combined with PROMACTA cliff, expect additional realignment announcements in 2025–2026.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo